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Cell deathTransglutaminase 2 (TG2) is the most widely distributed member of the transglutaminase family with almost
all cell types in the body expressing TG2 to varying extents. In addition to being widely expressed, TG2 is an
extremely versatile protein exhibiting transamidating, protein disulphide isomerase and guanine and ade-
nine nucleotide binding and hydrolyzing activities. TG2 can also act as a protein scaffold or linker. This unique
protein also undergoes extreme conformational changes and exhibits localization diversity. Being mainly a
cytosolic protein; it is also found in the nucleus, associated with the cell membrane (inner and outer side)
and with the mitochondria, and also in the extracellular matrix. These different activities, conformations
and localization need to be carefully considered while assessing the role of TG2 in physiological and patho-
logical processes. For example, it is becoming evident that the role of TG2 in cell death processes is dependent
upon the cell type, stimuli, subcellular localization and conformational state of the protein. In this review we
discuss in depth the conformational and functional diversity of TG2 in the context of its role in numerous cel-
lular processes. In particular, we have highlighted how differential localization, conformation and activities of
TG2 may distinctly mediate cell death processes.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Transglutaminase 2 (TG2, EC 2.3.2.13) is a member of the transgluta-
minase family that catalyzes thiol- andcalcium-dependent transamidation
reactions. The transamidation reaction catalyzed by the transglutami-
nase family results in the formation of a covalent bond between the
γ-carboxamide group of a peptide bound glutamine residue and a pri-
mary amine group. The ε-amino group of a peptide bound lysine can
act as the amine donor for the reaction; in this case a covalent crosslink
is established between the γ-carboxamide group of the glutamine and
the ε-amino group of lysine [1]. TG2 is themost ubiquitously expressed
and most studied member of the family. In addition to its transamidat-
ing activity, it has been shown to bind and hydrolyze GTP and ATP. Al-
though ATP/ADP binding has no effect on transamidating activity [2],
calcium and GTP/GDP binding inversely regulate the transamidating ac-
tivity of TG2; that is, TG2 is only active as a transglutaminase when
bound to calcium and inactive when bound to GTP/GDP [3,4]. However,
in the GTP/GDP bound form, TG2 is proposed to be involved in regulat-
ing signal transduction by acting as a G-protein which transduces a sig-
nal from α1-adrenergic, oxytocin and thromboxane receptors [5–7].
Moreover, recent developments show it truly is a multifunctional pro-
tein as it is proposed to function as a protein disulﬁde isomerase (PDI)ology, University of Rochester,
1 585 276 3740; fax: +1 585
u (G.V.W. Johnson).
l rights reserved.[8,9], protein kinase [10,11], protein scaffold [12,13]; even as a DNA hy-
drolase [14].
This unusualmultifunctionalitymay be surprising atﬁrst, but amore
careful analysis of the evolutionary roots of TG2 might, in part, shed
light on the issue. The transglutaminase family has 9members in higher
vertebrates: TG1-7, band 4.2 and factor XIII [1]. All, except band 4.2, re-
tain the ability to catalyze transamidation reactions. Band 4.2 on the
other hand, although not catalytically active, still retains important
functions such as scaffolding [15]. TG2 is the most widely expressed
member of the family and almost all cell types in the body express
TG2 to varying extents; it therefore was previously called “tissue trans-
glutaminase”. Furthermore, almost all cell types in the body express at
least one additional catalytically active transglutaminase in addition to
TG2 [16]. This is a suitable evolutionary background for a protein to de-
velop alternative functions other than the primary function. The prima-
ry function of TG2, which is transamidation, being partly carried out by
other transglutaminases may have provided a permissive environment
for TG2 to develop alternative functions. According to the prevailing
theory, all the transglutaminase familymembers are derived froma sin-
gle transglutaminase gene; and the ﬁrst transglutaminase gene shares a
common ancestorwith calpain-type cysteine proteases [17,18]. The fact
that organisms as primitive as bacteria have the transglutaminase en-
zyme indicates that the appearance of the ﬁrst transglutaminase gene
occurred very early in evolution [19] (although it is believed that verte-
brate transglutaminases did not evolve from bacterial transglutami-
nase, but rather they evolved convergently). Up through lower
vertebrates, only a single transglutaminase gene is found in the genome
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broad classes of transglutaminases, occurred in early vertebrate evolu-
tion. As a result of this early duplication, class I (factor XIII and TG1)
and class II (TG2-7 and band 4.2) transglutaminases evolved [17]. It is
well documented in the literature that gene duplication can result in
the acquisition of new functions by the proteins whose genes have
been duplicated [20,21]. This evolutionary background and the func-
tional redundancy offered by other transglutaminases likely lay at the
basis of the multifunctionality of TG2. Despite its new functions, TG2
retained its original function of transamidation. However, to what ex-
tent transamidation activity of TG2 plays a role in normal physiology
is still under discussion.
2. TG2: transamidating/deaminating function
The ﬁrst demonstration of transamidation activity was in 1957 in a
research article titled “An enzymatically catalyzed incorporation of
amines into proteins” [22]. They named the enzyme responsible for
this activity “transglutaminase”. By the mid-1980s it was clear that
this “transglutaminase” activity was the product of more than one en-
zyme [23]; a ﬁnding that ultimately resulted in the characterization of
a whole enzyme family. TG2 has been the most studied member of
the family; therefore much of our knowledge about transglutaminase
reactions comes from the studies of TG2, and to some extent, from
factor XIII as well. Today we know the mechanism of the reaction cat-
alyzed by TG2, which takes place in two steps, in great detail. At the
ﬁrst step, the sulfur of the active site cysteine (C277) performs a nu-
cleophilic attack on the γ-carbon of the peptide bound glutamine side
chain (which is the acyl-donor) and forms a thioester bond between
C277 and the substrate. An ammonia molecule is released at this step
as a byproduct. At the second step, the thioester bond is attacked by a
primary amine or water (which is the acyl-acceptor). If the attacking
group is a primary amine (either a small biological amine or the
ε-group of a peptide bound lysine), the reaction is called transamidation;
if it is a water molecule it is called deamination [24] (Fig. 1).
Transamidation reactions have two major outcomes: addition of
the small biological amine to the protein when the attacking group
is a small primary amine or formation of an isopeptide bond between
acyl-acceptor and acyl-donor peptides (Fig. 1b). The addition of a
small biological amine can be considered as a post-translational mod-
iﬁcation and it changes the properties of the substrate proteins.
Isopeptide bonds (Fig. 1c) are resistant to chemical and physical dis-
ruptive forces; therefore they have been suggested to have functional
signiﬁcance in stabilizing the extracellular matrix and in preventing
the release of intracellular contents of apoptotic cells to the extracel-
lular milieu [1,25,26]. Isopeptide bonds are not the only way to cross-
link two proteins: a small amine can mediate the formation of an
indirect crosslink (Fig. 1d).
The deamination reaction has only one outcome: the conversion of
the acyl-donor glutamine residue to a glutamate residue (Fig. 1a). For
many years, it was believed that the deamination reaction took place
only when the availability of primary amines as acyl-acceptor was lim-
iting and water played this role due to its abundance. At best, deamina-
tion reactionswere believed to be favored only under certain conditions
such as lower than physiological pH [27]. It was rarely, if at all, consid-
ered that TG2might actually deaminate a protein evenwhen conditions
were permissive for transamidation until a study showed that a gluta-
mine residue in Hsp20 was speciﬁcally deaminated while other gluta-
mine residues were transamidated [28]. Further studies showed that
speciﬁc deamination is observed in other proteins as well [29], and
the number of reports examining the structural features of substrates
that favor deamination over transamidation is growing [29,30].
The ‘TRANSDAB wiki database’ (http://genomics.dote.hu/wiki/
index.php/Main_Page) currently lists 140 substrates of the transami-
dase function of TG2 (For more detailed information about TG2 sub-
strates, see Grifﬁn et al. [1]). It is likely that most of these substratesare modiﬁed by TG2 in speciﬁc conditions and that these conditions
are likely determined by various factors. The factors controlling trans-
amidation/deamination activity and the signiﬁcance of these activi-
ties in cell physiology will be discussed in detail below.
3. TG2: GTPase/G-protein function
The ﬁrst demonstration that TG2 can bind to and hydrolyze GTP
came in 1987 [31]. In that study, the authors also showed that calcium
binding and GTP binding were competitive and a transamidating in-
active mutant of the active site cysteine retained its GTP hydrolyzing
activity. The real breakthrough in the ﬁeld, however, was the demon-
stration that TG2 and Gαh are the same protein [6]. In the original
study, TG2 was shown to be the functional α-subunit of a G-protein
associated with α1 adrenergic receptor signaling, carrying the signal
to phospholipase C-δ1. Further studies from other groups have
added to the receptor types with which TG2 can interact. TPα throm-
boxane A2 receptor [7] and oxytocin receptor [5] were also shown to
exploit TG2 as a G-protein. The physiological signiﬁcance of TG2 act-
ing as a G-protein is still unclear since the number of studies on this
topic has been limited and the results are controversial [32,33].
The inhibitory effect of guanine nucleotide binding by TG2 on its
transamidase activity has been very well documented [31]. The ap-
proximations for IC50 of GTP range from ~300 nM to 6 μM [34,35]. De-
termining the afﬁnity of TG2 for calcium ions has been more difﬁcult
since there are at least 3 (more likely 6) calcium binding sites with
very different afﬁnities for calcium. However what is very clear is
that the intracellular average GTP/calcium ratio (~150 μM/~100 nM)
is more than sufﬁcient to keep TG2 in a relatively latent state as a
transamidase. Certain splice variants or single site mutants of TG2
that lack guanine nucleotide binding capability are more prone to ex-
hibit transamidating activity in situ as expected [3,34,36,37]. Further-
more, groups that have studied GTP-binding defective forms of TG2
have concluded that the loss of GTP binding renders the enzyme
more proapoptotic [36,38,39]. Nonetheless, it is still controversial
whether the loss of guanine nucleotide binding makes TG2 more
proapoptotic per se, or is it because the loss of binding promotes the
transamidating activity of the protein [36,38]. Although further stud-
ies are required to clarify this issue, it should be noted that these are
not mutually exclusive hypotheses and both could be true depending
on the context.
In addition to cell death, different isoforms may affect cell differ-
entiation in opposing directions. In a recent study [39], it was found
that GTP-binding defective short form of TG2 (TG2-S) induced neuro-
blastoma cell differentiation, whereas long form (TG2-L) suppressed
it. Importantly, transglutaminase inhibitors prevented TG2-S induced
differentiation, which strongly suggests that the main driver of differ-
entiation is the elevated transamidating activity due to GTP binding
[39]. This conclusion is also in line with a previous report from our
group [40].
4. TG2: kinase function
Although the GTPase activity of TG2was associatedwith its suggested
G-protein function, no functional outcome of the ATPase activitywas pro-
posed until Mishra et al. provided data suggesting that TG2 has intrinsic
kinase activity [10]. In their original paper [10] and in the follow up stud-
ies that came from the same laboratory [11,41–43], the authors reported
that TG2 phosphorylates insulin-like growth factor-binding protein-3
(IGFBP-3) [10], histones [11], p53 [42] and retinoblastoma protein [43].
The in vitro phosphorylation experiments were conducted with a variety
of TG2 preparations from commercial to recombinant TG2, all of which
exhibited kinase activity. The use of different TG2 preparations decreases
the chance of the presence of a contamination and clearly indicates that in
vitro TG2 can act as a kinase. However, whether TG2 does or does not act




Fig. 1. Reactions catalyzed by the transamidase activity of TG2. (a) TG2 can use a water molecule as an acyl-acceptor to deaminate a peptide-bound glutamine residue and convert it
to a glutamate residue. (b) When a primary amine acts as acyl-acceptor, the glutamine residue is modiﬁed resulting in a posttranslational modiﬁcation. (c) An isopeptide bond
forms when the ε-group of a peptide bound lysine is the acyl-acceptor resulting crosslinking of two proteins. (d) The crosslink does not have to be an isopeptide bond. A primary
amine can act as a crosslinker between two proteins.
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vide evidence that anothermember of the transglutaminase family, factor
XIII, has kinase activity aswell [42]. For this to be true, factor XIII must ex-
hibit ATPase activity. This issue has not been studied, but an early report
showed that factorXIII canbe inhibitedbyATP [44],which is an indication
of ATP binding to factor XIII and supportive of the claim that factor XIII has
kinase activity.
5. TG2 as protein disulphide isomerase (PDI) and a regulator of
mitochondrial function
Compared to the proposed kinase activity, the PDI activity of TG2 is
relatively well-established. First of all, there are several studies describ-
ing proteins with both transamidase and PDI activities [45–47]. There-
fore, the demonstration of the PDI activity of TG2 was not without
precedent. The original report which showed TG2 has PDI activity [8]
clearly demonstrated that transamidase active site cysteine (C277) is
not required for PDI activity. In this study TG2 converted inactive/
denatured RNase A into an active enzyme by the formation of correct
disulphide bonds. PDI activity of TG2 was shown to be independent of
its transamidation activity, did not require calcium and was not inhib-
ited by nucleotides. Given that concentrations of nucleotides are high
and calcium are low in the cytosol, the authors suggest that TG2 may
be acting as a PDI in this compartment [8]. Similar to the kinase case,
factor XIII was shown to have PDI activity as well [48], independent of
its transamidating activity.
The ﬁrst evidence showing that TG2 acts as a PDI in vivo came
from the studies focusing on mitochondrial TG2 [9]. In this study,
the authors found a decrease in the disulphide bond content of mito-
chondrial respiration complexes in tissues from TG2−/− mice; sug-
gesting that TG2 acting as a PDI facilitated the formation of disulﬁde
bridges in mitochondrial complex I, II and V [9]. They also found a de-
crease in ATP levels in the TG2−/− mice cardiomyocytes and skeletal
muscle cells, and suggested a causal relationship between the ab-
sence of TG2, decreased disulphide bond content and decreased ATP
levels [9,49]. Although this causality is yet to be established, the exis-
tence of this correlation is an important observation itself.
In a recent study, a mitochondrial protein, the adenine nucleotide
translocator 1 (ANT1), was shown to interact with TG2 and suggestedto be a substrate for both transamidase and disulphide isomerase ac-
tivities of TG2 [50]. ANT1 is an important permeability transition pore
(PTP) subunit, therefore it is very important for mitochondrial func-
tion. Data was presented suggesting that ANT1 polymerization is pre-
vented by TG2's PDI activity [50]. In TG2−/− mice ANT1 was found to
be amore polymerized state than inwild typemice, and ADP/ATP trans-
porter activity was enhanced in heart mitochondria from TG2−/−mice.
Acceleration of ANT1 transporter activity might exert protective effects
in the case of an impairment of mitochondrial activity. Interestingly,
TG2−/− MEFs are particularly sensitive to atractyloside, which binds
to outward facing conformation of ANT1 and blocks it, suggesting that
TG2 affects the orientation/conformation of ANT1. Considering that
PDI activity of TG2might also contribute to the stabilization of the respi-
ratory complexes [9], the overall ATP homeostasis could be affected by
the absence of TG2, or with upregulation of TG2 due to stressors [50].
Although many studies suggest that the PDI activity of TG2 is cru-
cial for its role in mitochondrial function, it is not always clear how
TG2 modulates mitochondria-dependent processes. In an earlier
study, TG2 overexpression led to increased cell death in response to
staurosporine (STS) treatment possibly through increased cyto-
chrome c release [51]. In this study, TG2 overexpressing cells showed
hyperpolarized mitochondria and elevated levels of reactive oxygen
species (ROS) under normal conditions. Inhibition of mitochondrial
transition pore openingwith Cyclosporin A (CsA) or adding antioxidants
like N-acetylcysteine (a thiol supplier) or L-acethylcarnitine (natural
compound to increase energy charge) prevented STS-induced cell
death in TG2 overexpressor cells, however there was no affect of CsA
on mitochondrial hyperpolarization due to TG2 overexpression. There-
fore, the authors suggested that TG2 may alter the redox state of the
cell which could contribute to the potentiation of STS-induced cell
death [51]. In contrast, overexpression of TG2 in striatal cells enhanced
mitochondrial membrane depolarization in response to thapsigargin.
However, enhanced thapsigargin-induced ROS production as well as in-
creased cytochrome c release, caspase-3 activation and cell death were
observed [52]. Given these conﬂicting results, it is likely that the poten-
tiation of cell death with increased TG2 expression is not directly due
tomitochondrial hyperpolarization. It has also been suggested that a pu-
tative BH3 domain in TG2 may be involved in the increase in STS-
induced cell death in TG2 overexpressing cells [53]. In this study an
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showed 70% identity with the BH3 domain of Bcl-2 was identiﬁed [53].
It was suggested that this region could result in TG2 dimerizing and tak-
ing on a conformation like Bax. Deletion of the putative BH3 domain or
mutation of L204E (the amino acid critical for homo/hetero-dimeriza-
tion of Bax) abolished the sensitization of TG2 overexpressing cells to
STS-induced cell death. However, the authors did not address the fact
that deleting the putative BH3 domain of TG2 might also disrupt the
transamidation activity of TG2. Therefore, the prevention of cell death
sensitization could be due to absence of transamidation activity in the
mutant forms. The same study also showed that TG2 can interact with
Bax, and the BH3 domain of TG2 causes translocation of Bax to mito-
chondria and induces cytochrome c release [53]. However there was
no interaction between TG2 and Bcl-2 or Bcl-XL, the antiapoptotic pro-
teins. It is also suggested that TG2 transamidates Bax protein, leading
to its polymerization at the mitochondria level. The interaction between
TG2 and Bax was also increased in response to cell death induction
with STS. However, this result might be also due to the fact that cell
death induction can cause an increase in the expression level of Bax
protein, with a secondary effect being an increase in the levels in the
co-immunprecipitates [53].
A signiﬁcant issue that needs to be considered when evaluating the
effects of TG2 on mitochondrial function is the fact that ﬁndings indicate
that TG2 is not inside mitochondria (Fig. 2). Although there is calcium-
dependent transamidating activity in puriﬁed mouse mitochondria and
mitoplast, the activity was similar in mitochondria from wild type and
TG2−/−mice. In addition, TG2 could not be detected in themitochondrial
fractions [54]. However, it does not exclude the possibility that TG2might
interact with or modify the proteins present on the outside of the
mitochondria as has been suggested [53]. Indeed the majority of TG2 is
loosely associated with mitochondria as it is easily removed by digitonin
treatment [50] (Fig. 2). The possibility of other transglutaminases being inFig. 2. Localization of TG2 in the cell. TG2 has no known signal sequence, and is primarily loc
localized in the nucleus, although the mechanism(s) by which it enters the nucleus has not
suggests that it is associated with mitochondria, but not found in the mitochondria. TG2 is a
into the matrix.themitochondria, aswell as the lack of a good antibodywhich recognizes
mouse TG2 speciﬁcally, has hindered studies on the role of TG2 in the
mitochondria. Further studies are clearly needed to fully delineate the
role of TG2 in modulating mitochondrial function.
6. Structure/Function relationship of TG2
Themultifunctionality of TG2 is dependent on the structural features
of TG2. TG2 is comprised of 4 domains: an N-terminal β-sandwich do-
main (aa 1–140), the catalytic core (aa 141–460) and two C-terminal
β-barrel domains (aa 461–586 and 587–687) [55]. The crystal structure
of TG2 is available in its GDP bound closed form [55], ATP bound closed
form [56] and inhibitor bound open form [30], which have been invalu-
able for our understanding of the structure and function of TG2.
The site of transamidating activity is composed of the catalytic
triad of cysteine proteases (Fig. 3); cysteine 277 (C277), histidine
335 (H335) and aspartate 358 (D358), which are the critical residues
for transamidating activity [55]. The cysteine to serine mutation at
the position 277 (C277S) has been extensively used to inactivate
the transamidation function of TG2 [1]. Although this mutation
knocks out all transamidating activity, it results in a conformational
change which greatly impairs the GTP/GDP binding capability as
well and increases the propensity of the protein to exist in an open
conformation [3,36]. In addition to the catalytic triad, two conserved
tryptophan residues (W241 [Fig. 3] and W332), located at the oppo-
site sides of the “catalytic tunnel”, are critical for the transamidating
activity, since these residues stabilize the enzyme-thiol intermediate
that forms during catalysis [30,57]. Mutating W241 to an alanine
(W241A) knocks out transamidating activity without any effect on
GTP/GDP binding [30,36]. In contrast, a W332F-TG2 mutant was sig-
niﬁcantly impaired in its ability to bind GTP/GDP [57]. A threonine
residue (T360) at the entrance of the catalytic tunnel controls thealized in the cytosolic compartment. However, a small but signiﬁcant portion of TG2 is
yet been fully deﬁned. Although TG2 can modify mitochondrial enzymes, the evidence
lso found outside of the cell, both associated with the plasma membrane and deposited
Fig. 3. Transamidase active site of TG2. The catalytic site of transamidating activity is composed of the catalytic triad: Cys277, His335 and Asp358. A conserved tryptophan residue,
Trp241 is also critical for the transamidating activity. A hydrogen bond forms between Cys277 and Tyr516 in the closed conformation of TG2, which is believed to further stabilize
the closed conformation and keep the enzyme inactive.
410 S. Gundemir et al. / Biochimica et Biophysica Acta 1823 (2012) 406–419entry of the acyl-acceptors for the second step of the catalysis. The
mutation of this residue (T360A) very signiﬁcantly increased the
preference for deamination over transamidation [30]. Another impor-
tant residue in the catalytic site is the tyrosine residue at the position
516 (Y516). As shown in Fig. 3, a hydrogen bond forms between C277
and Y516 in the closed conformation of TG2 which is believed to fur-
ther stabilize the closed conformation and keep the enzyme inactive
[30]. Although the exact effect of loosening this hydrogen bond is
not clear, mutating this residue to phenylalanine (Y516F) rendered
TG2 more prone to an open conformation [3].
ATP and GDPwere found to bind the same nucleotide binding pock-
et [55,56]. It is a perfect example of a tertiary pocket, with contributing
residues from the catalytic domain, β-barrel-1 and β-barrel-2 domains
(Fig. 4). It is composed of at least ten residues, many of which are in-
volved both in adenine and guanine nucleotide binding; however,
S482 and R580 were found to be involved only in guanine, not adenine,
nucleotide binding [56]. Therefore, if one wants to decrease the afﬁnity
of TG2 for guanine nucleotides selectively, the arginine residue located
at position 580 (R580) is the best candidate. It interacts with the gua-
nine nucleotide at several points and its mutation to alanine (R580A)
resulted in the almost complete loss of GTP/GDP binding activity and
a disinhibition of transamidase activity [3,36,58]. It should be noted,
however, that the R580A mutation does not necessarily decrease the
GTPase activity of TG2. TG2, due to its high afﬁnity for GDP as well as
GTP, is likely to spend signiﬁcant time in the GDP bound form after
the hydrolysis of GTP. Therefore, there is a prolonged ‘docking time’
for the replacement of GDPwith a newGTPmolecule. The R580Amuta-
tion decreases the afﬁnity for both GTP and GDP; therefore, it has op-
posing effects on the GTP hydrolysis rate. On the one hand, this
mutation enhances the rate by decreasing the afﬁnity for GDP —
hence less docking time is required; on the other hand it reduces the
rate by decreasing the afﬁnity to GTP. In addition, this mutation might
have an effect on the catalysis process per se. Overall, the effect of this
mutation on GTP hydrolytic rate is to be determined, but it is clear
that the R580A mutant spends much less time in guanine nucleotide
bound form compared to wild type. Lastly, although not shown in
Fig. 4, S171 and K173 residues are very important for GTPase function
[38,59].
Unlike the nucleotide binding pocket, we do not have structural in-
formation about the calcium binding motifs since the crystal structures
were obtained in the absence of calcium [30,55]. However, thestructures of two transglutaminases are known in the calcium bound
state: factor XIII [60] and TG3 [61,62]. Structural prediction studies
based on other transglutaminases, calorimetric studies and site directed
mutagenesis studies have been conducted to help elucidate the calcium
binding sites of TG2 [63–65]. The prevailing consensus is that TG2 has 6
calcium binding sites all of which are located in the catalytic domain
[65]. There is little enthalpy change due to calcium binding, which sug-
gests the binding energy is used for entropic change, which means
structural change. It is plausible to argue that the free energy required
for the dramatic conformational change comes from calcium binding,
at least in part. Furthermore, there is evidence that suggests there is
cooperativity among binding sites [65], that is, binding of calcium to
certain sites might trigger the binding of additional calcium ions. The
highest afﬁnity site is 228VNCNDDQGV236, and mutating this site pre-
vents binding ofmore than one calcium ion due to cooperativity.Mutat-
ing any of the calcium binding sites decreased transamidating activity,
but mutating 3 of the 6 binding sites completely abolished it. As
expected, mutating calcium binding sites does not have a dramatic ef-
fect on GTPase activity [65]. Overall, although we lack the crystallo-
graphic evidence for calcium binding, studies exploiting alternative
methods have partially made up for this shortcoming.
Theoretically and experimentally, there is little doubt that transa-
midase activity of TG2 tends to increase as the [calcium]/[guanine nu-
cleotide] ratio increases. Therefore, it is reasonable to expect TG2 to
be largely silent as a transamidating enzyme inside the cell where
this ratio is very low; and enhanced activity outside the cell where
there is virtually no GTP or GDP, but millimolar levels of calcium.
However, experimental evidence suggests otherwise: extracellular
TG2 appears to be inactive unless there is a physical or a chemical
stressor [66]. This observation argues for the existence of additional
control mechanisms for transamidating activity of TG2 other than cal-
cium and guanine nucleotides. Redox state of the environment might
be important for the regulation of TG2 activity as this protein is sug-
gested to bear at least ﬁve intramolecular disulphide bridges [8]. In
a recent study, two of these disulphide bonds (between C370 and
C371 and between C370 and C230) were shown to play role in inac-
tivation the transamidase activity of TG2. A disulphide bond that
forms between C230 and C370 facilitates the formation of a disul-
phide bond between C370 and C371 which results in inactivation of
the transamidase activity of TG2. [67]. The formation of the C370–
C230 disulphide bond occurs in a less oxidizing environment than
Fig. 4. Guanine nucleotide binding pocket of TG2. The guanine nucleotide binding pocket is an example of a tertiary pocket, with contributing residues from the catalytic domain, β-
barrel-1 and β-barrel-2 domains. Arg580 interacts with the guanine nucleotide at several points; loss of this residue signiﬁcantly impairs GTP/GDP binding activity and disinhibits
transamidase activity. Dashed green line depicts optimal H-bonding distance; dashed white line depicts suboptimal H-bonding distance.
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the presence of calcium. The authors argue that the presence of
these disulphide bonds in high calcium environments, like extracellu-
lar milieu, helps to keep TG2 inactive as a transamidase. Intriguingly,
one of these inactivating disulphide bridges, C230–C370 bond, is ob-
served in the ATP bound closed form [56]. Given that ATP has been
reported not to inhibit TG2 [2], or was 100 times less effective in inhi-
biting the enzyme compared to GTP [68], it maybe that ATP-bound
TG2 is amendable to the calcium-induced open conformation – and
possibly – subsequent inactivation in an oxidizing environment by
formation of the C370-C230 disulphide bond.
It is not uncommon to see complex regulatory mechanisms, such
as redox control, modulate different activities of multifunctional pro-
teins like TG2. It would be expected to see very high utilization of
posttranslational modiﬁcations to regulate TG2, as well; but, there is
only a limited number or studies reporting posttranslational modiﬁ-
cations of TG2. However, this issue is beginning to be addressed as
two recent publications provide evidence that TG2 is SUMOylated
[69] and S-nitrosylated [70]. In the ﬁrst study, the authors found
ROS-dependent SUMOylation of TG2, which decreased its ubiquitina-
tion and degradation. This shows that the redox state has amore compli-
cated effect than simple inactivation of transamidase activity [69]. In the
second study, it was shown that nitric oxide mediates S-nitrosylation of
TG2 which inhibits transamidase activity [70]. Given the role of nitric
oxide in endothelial cells, this regulatory mechanism may be especially
important for vascular TG2. Indeed, the authors in the same study found
that the aging process decreases S-nitrosylation of TG2 which in turn
may contribute to arterial stiffness in the elderly [70]. Lastly, it has been
reported that TG2 is phosphorylated by PKA and that this phosphoryla-
tion regulates its binding to 14-3-3 protein [41]. The report solely relies
on in vitro data, thus awaits conﬁrmation by ex vivo and in vivo studies.
Further studies might reveal additional posttranslational mechanisms
that are involved in themodulation of TG2 activity addingmore complex-
ity to the already sophisticated regulatory network.
As opposed to the relatively well-studied mechanisms regulating
its enzymatic activity, there is very little information regarding what
controls the subcellular localization of this protein. TG2 is primarily
cytosolic with small quantities found in the nucleus [71,72], on theouter side of the plasma membrane [73,74], and secreted to the extra-
cellularmatrix [75]. Intriguingly a recent study suggested thatmicrove-
sicles which are shed by certain cancer cells contain TG2, which is not
only a process bywhich TG2 could be externalized, but could also result
in the transfer of TG2 to other cells [76]. Externalization of TG2 by a
mechanism that involves targeting to perinuclear recycling endosomes
has also been recently described [77]. Recently two putative nuclear lo-
calization signals (259DILRR263 and 597PKQKRK602) have been identiﬁed
in TG2, butmutation of one site resulted in inactivation of the transami-
dating activity and therefore was not used in the study to examine TG2
localization. In addition,mutation of the second sitewas combinedwith
a nuclear export signal [78] and therefore the effects of these putative
nuclear localization signals on the intracellular localization of TG2 re-
main undetermined. Although these recent studies are intriguing, the
mechanisms involved in the localization of TG2 to these different cell
compartments still require further examination.
7. Control of TG2 expression
The expression of TG2 is thought to be mainly controlled at the
transcription level [1]. The human TG2 promoter is extremely respon-
sive to various activators [79] (Fig. 5). Sp1 binding sites are very com-
monly observed in human promoters and the TG2 promoter has 4 Sp1
binding sites [1,79,80]. The most well known activators of TG2 are
retinoids and this activation is mediated via a tripartite response ele-
ment in the human TG2 promoter located approximately 1.7 kb up-
stream of the transcription start site [81]. The TG2 promoter has a
functional transforming growth factor β1 (TGF-β1) response element
approximately 0.9 kb upstream of transcription start site [82]. How-
ever, the relationship between TG2 and TGF-β is a complicated one,
and will be discussed in more detail below in the section on cell sur-
face TG2: A cue for survival, proliferation and migration. Response el-
ements for two very important stress induced transcription factors
are located on the TG2 promoter: NF-κB [79,83] and hypoxia induc-
ible factor (HIF) [84] (Fig. 5). Tumor necrosis factor α (TNF-α),
which is highly upregulated under inﬂammatory stress, is another
well known inducer of TG2; other inﬂammatory cytokines, such as in-
terleukin 1 β (IL1β) or interleukin 6 (IL6), can also upregulate TG2
Fig. 5. Regulatory elements of the human TGM2 gene expression. The expression of TG2 is regulated by many factors. In this ﬁgure identiﬁed elements that regulate TG2 expression
are shown. Retinoic acid response elements: RRE-1 (−1731), RRE-2 (−1720), glucocorticoid response element: GRE (−1399), nuclear factor кB response element: NF-кB
(−1338), interleukin-6 response element: IL-6 (−1190), tumor growth factor-β1: TGF-β1 (−900), activator protein-2: AP-2 (−634), hypoxia response element: HRE (−367),
activator protein-1: AP-1 (−183), CAAT box (−96), GC box: Sp1 binding motifs (−54, −43, +59, +65), TATA box (−29), nuclear factor-1: NF-1 (+4, +12).
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response elements in the TG2 promoter in the future.
The TG2 promoter not only serves as a venue for induction, but it
also plays a role in silencing of TG2 expression. TG2 expression gener-
ally correlates with aggressiveness in cancer cells [89]. In a breast
cancer cell model, it was shown that CpG islands in the TG2 promoter
are hypermethylated, therefore TG2 expression is epigenetically si-
lenced in less aggressive cell types [90]. Very similar observations
were made in non-small cell lung cancer [91] and in glioma [92].
These studies provide strong evidence for the utilization of epigenetic
methylation as a means to silence TG2 expression in various cancers.
Another mechanism for downregulating TG2 promoter activity in-
volves histone deacetylases (HDACs). Liu et al. showed that in a neu-
roblastoma model N-myc protein transrepressed the activity of the
TG2 promoter, hence TG2 expression, by recruiting HDAC1 to an
Sp1 binding site on TG2 promoter [93]. These studies demonstrate
how actively the TG2 promoter is regulated by transactivation, trans-
repression and epigenetics; which may be an indication of the impor-
tance of TG2 expression to the cell. Overall, TG2 is generally
upregulated under stress conditions and it can be categorized as a
stress response protein [94]. This upregulation in TG2 levels is proba-
bly part of a cellular protective response. However, if the insult is ex-
cessive and the cellular demise is inevitable, TG2 may also facilitate
cell death [1].
Very intriguingly, several stress conditions and inducers have
been shown to result in the expression of different isoforms of TG2
[34,95–99]. In response to retinoic acid [95,96] and cytokines [99] dif-
ferent splice variants were observed in different models. Similarly,
central nervous system pathologies such as Alzheimer disease [97]
and acute spinal cord injury [98] caused upregulation of certain iso-
forms. The most important common feature of these variants is that
they all lack certain segments of the C-terminal region of TG2 and
there are variations in the amino acid sequence at certain points. Sev-
eral amino acids in the C terminal region contribute to the guanine
nucleotide binding pocket; therefore deletion of a these residues sig-
niﬁcantly diminishes the afﬁnity for GTP [34]. It is largely unknown
how these splice variants are generated. The sequence differences
make the conventional alternative splicing mechanisms unlikely. At
least some of these variants are likely formed due to intronic read-
throughs [34,95,97–99]. Further studies are required to clarify the
mechanisms by which these variants are generated and the role of
each variant in normal physiology and pathology.
8. TG2 regulates cell survival/death processes
The multifunctional nature of TG2 complicates determining the
role it plays in cell physiology and pathology. For example, the role
of TG2 in the cell death/survival process is extremely complex, and
circumstances in which TG2 acts as a prodeath or prosurvival protein
is an area of active investigation. Relatively early studies from our lab
clearly show that TG2 modulates caspase-dependent programmed celldeath [100,101]. However, there is evidence indicating that TG2 can
modulate other modes of controlled cell death. TG2 activity was
reported to induce the release of apoptosis inducing factor (AIF) from
mitochondria in pancreatic ductal adenocarcinoma cells and trigger
caspase-independent apoptosis [102]. Very intriguingly, TG2 was
found to inhibit autophagy in the same cell line [103]. A recent report
from a different group showed that autophagosomes cannot mature
in the absence of TG2 and acidiﬁcation does not occur [104]. Neither
of the studies determined whether transamidase activity is required
for the role of TG2 in autophagy [103,104]. A recent paper, however,
provided evidence that suggests transamidase activity might be in-
volved in the ﬁnal steps of autophagosome maturation [105].
Many of the initial studies which investigated the relationship be-
tween TG2 and cell death relation were conducted in neuronal
models. This was mostly because TG2 is the most prevalent neuronal
transglutaminase [106–108], and in the human brain increases in TG2
expression have been observed in a number of chronic or acute neu-
ropathological conditions [109]. Due to this upregulation, it was hy-
pothesized that TG2 facilitates neuronal cell death in
neurodegenerative diseases. This hypothesis has been supported by
studies in which crossing of Huntington disease transgenic mice
with TG2−/− mice resulted in a signiﬁcant delay in the onset of
motor dysfunction and prolonged survival of the Huntington disease
transgenic mice [110,111]. However, the reason that TG2 deletion in
the Huntington disease mouse model is beneﬁcial is unclear; TG2
knockout mice per se are phenotypically normal with no apparent
deﬁcits in the major apoptotic pathways [33,112]. Further analyses
are required to determine how deletion of TG2 is protective in these
Huntington disease models.
Further evidence for the cell death promoting function of TG2 in
neurons has come from studies in transgenic mice that overexpress
human TG2 selectively in neurons (hTG2 mice). Even though pheno-
typically normal, hTG2 mice exhibited a dramatic increase in neuro-
nal damage in the most sensitive hippocampal regions in response
to kainic acid treatment [113]. However, there is also evidence sup-
porting an alternative theory: that TG2 upregulation might be the
neuron's response to stressful conditions and might be protective.
For example, as will be discussed below, TG2 is upregulated in brain
ischemia models, but this upregulation is protective, possibly due to
nuclear accumulation and regulation of transcription [36,114,115].
Clearly not only the cellular context, but also the speciﬁc stressor or
pathological conditions are important factors in determining whether
TG2 will facilitate or ameliorate cell death processes.
Overall, the mechanisms by which TG2 facilitates cell death or
protects cells are complex, case speciﬁc and still under investigation.
However, there are two relatively well described mechanisms that
are widely exploited by TG2 to control cell death/survival processes:
(i) mediating cell to extracellular matrix (ECM) contacts, thereby
triggering cell survival signaling; (ii) controlling the activities of tran-
scription factors directly or indirectly to promote survival or facilitate
demise.
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The fact that TG2 is present on the cell surface has been known for
a long time, but until recently it was widely believed that the major
role of extracellular TG2 was to stabilize ECM through forming iso-
peptide bonds among ECM proteins [116–118]. Although this func-
tion of TG2 is still thought to be important, recent evidence clearly
show that its function is more complicated than originally thought.
In a matter of several years, a paradigm shift occurred in the ﬁeld
which was triggered by the realization that TG2 is an extremely im-
portant cell surface protein with consequential functions for regulat-
ing cell survival, proliferation and migration [74,75].
The ground breaking work was done in 1992 by Gentile et al.
[119]. In this initial study, the authors showed that overexpression
of TG2 in a ﬁbroblast model increased adhesion of the cells to the sub-
stratum [119]. However, this important study fell short of showing
that it was extracellular TG2 mediating the increased adhesion. As a
matter of fact, the ﬁrst direct demonstration of cell surface TG2
came seven years later with the evidence demonstrating that the pro-
tein is concentrated at the points of cell adhesion [120]. It was long
known that TG2 can bind plasma ﬁbronectin with very high afﬁnity
[121], however more than 10 years pased until TG2–ECM ﬁbronectin
interactions and the importance of this binding in mediating TG2's
role in cell adhesion were discovered [122].
Fibronectin is a principal TG2 interactor in the ECM, but it is deﬁnite-
ly not the only one. TG2 can directly interact with at least 3 different
β-subunits of the integrin family: β1, β3 and β5 [74,123]. TG2 associa-
tion with β1 integrin did not prevent integrin-ﬁbronectin association;
they formed ternary complexes [123]. TG2–integrin–ﬁbronectin terna-
ry complexes are clearly involved in cell adhesion and migration [123].
Importantly, these ternary complexes activate certain intracellular
pathways, such as the focal adhesion kinase (FAK) and its downstream
PI3K/Akt survival pathway, resulting in increased cell survival and mi-
gration [124]. Furthermore, integrin-dependent signaling to RhoA and
its downstream target Rho-associated coiled-coil containing serine/
threonine protein kinase (ROCK) is increased by cell surface TG2 [73].
In a different study, TG2–ﬁbronectin complexes supported cell adhesion
and the formation of RhoA-dependent focal adhesions, which in turn
promoted cell survival [125]. In summary, cell surface TG2 is very im-
portant for integrin mediated cell signaling.
One of the consequential ﬁndings of cell surface TG2 research was
the demonstration that the main role of TG2 in cell adhesion and
spreading was not dependent on its transamidase activity. Catalyti-
cally inactive forms of TG2 retain their ability to function as ‘integrin
binding adhesion coreceptors for ﬁbronectin’ and mediate attach-
ment and migration on ﬁbronectin surfaces [75,123]. Indeed, it was
shown that under resting conditions, cell surface TG2 is not catalyti-
cally active, but activated upon injury [66]. These important studies
illuminated the importance of TG2 independent of its transamidase,
also probably GTPase, activity. There is growing evidence that this
‘scaffolding’ function might be important for intracellular TG2, as
well as cell surface TG2 [36].
Another interactor of TG2 in the ECM is TGF-β. As we mentioned
above, TGF-β can and does induce TG2 expression [82]. Intriguingly,
the extracellular transamidase activity of TG2 was shown to be im-
portant for plasmin-mediated activation of TGF-β [126]. TG2 was
also shown to increase TGF-β expression through activating the
NF-κB pathway [127]; thereby increasing the synthesis and deposi-
tion of matrix proteins. This result is in line with the evidence
obtained from TG2 knockout mice. Shweke et al. showed that TG2
knockout mice were protected against ﬁbrosis due to decreased rate
of collagen I synthesis. This decreased synthesis rate was, the authors
conclude, the result of decreased TGF-β activation in the absence of
TG2 [128]. It is also interesting that TG2−/− show signiﬁcantly less
pulmonary ﬁbrosis than wild type mice in response to bleomycin
and TGF-β causes an increase in membrane localized TG2 in cellmodels [129]. From these studies, it appears that there is a positive
feedback loop between TG2 and TGF-β.
The interactor list of extracellular TG2 is getting longer as new
interacting proteins are being reported almost every year. The TG2
interacting proteins and glycans other than ﬁbronectin and integrins
include: Collagen, vitronectin, osteopontin, nidogen, laminin, osteo-
nectin, osteocalcin [1], ﬁbronectinα, ﬁbronectin γ, substance p, endo-
statin, heparin [130], syndecan-4 [131], amyloid β-peptide [132,133],
MMP-2 [134] and VEGFR-2 [135]. The role of these interactions in cell
physiology requires further studies.
It is clear that the presence of TG2 on the cell surface increases at-
tachment to ﬁbronectin surfaces; however the effect of this attachment
onmigration and spreading is not entirely clear. Both increased and de-
creased cell migration as a result of TG2-mediated binding to ﬁbronec-
tin or collagen have been reported [13,75,136]. This could be explained
by the differences in model systems. The ability to migrate is especially
important in inﬂammation and cancer. Metastatic capacity of cancer
cells depends on their ability to migrate. Several studies from Mehta
and his colleagues have shown that TG2 increases the invasiveness
and metastatic capacity of certain cancer cells [89,137,138]. It should
benoted however, that any increase inmetastatic capacity ismost likely
mediated by the scaffolding function of TG2, and when transamidating
activity is involved, TG2 might actually decrease the migration and in-
vasion [139,140]. Evidence is accumulating showing the role of TG2
on the migration of inﬂammatory cells. In an elegant study, Mohan et
al. identiﬁed TG2 as a receptor thatmediates T-cell transendothelialmi-
gration [141]. In this study, TG2 was on the surface of endothelial cells,
simply guiding the migration of T-cells. This is in contrast to a more re-
cent study which proposed that enhanced TG2 expression in migrating
cells mediates migration through cell surface TG2–ﬁbronectin interac-
tion [142]. In this study, the authors speculate that cell surface TG2 con-
tributing to astrocytic inﬁltration ofmultiple sclerotic (MS) lesions, thus
contributes to inﬂammation. In a similar study, TG2 immunoreactivity
was found in MS lesions and it was postulated that the extracellular
TG2mediates astrocyte adhesion toﬁbronectin andmigration in the ex-
tracellular matrix of MS lesions [143]. The role of cell surface TG2 in in-
ﬂammation is not limited to guiding migration. Evidence from TG2
knockoutmice revealed that the phagocytic capacity of TG2 nullmacro-
phages to engulf apoptotic cells is impaired [144,145]. A more detailed
analysis revealed that in the absence of TG2, integrin β3 (which is in-
volved in the uptake of apoptotic cells bymacrophages and is a TG2 inter-
actor) cannot efﬁciently recognize the apoptotic cells to be engulfed,
among other deﬁciencies in phagocytic portal formation [146,147].
These deﬁciencies lead to an age dependent autoimmunity in TG2 knock-
out mice due to impaired clearance of apoptotic bodies [144,148]. Other
groups have also provided supporting evidence to the role of TG2 in apo-
ptotic cell clearance bymacrophages [149]. In short, the role of TG2 in cell
migration may represent a therapeutic intervention point in metastatic
cancers and inﬂammatory diseases.
A very interesting mechanism by which TG2 inhibits cell migra-
tion was recently deﬁned that warrants mentioning. TG2 was found
to act as a ligand for the atypical G-protein coupled receptor, GPR56
[150,151]. The binding of TG2 to GPR56 inhibited tumor growth and
metastasis. Due to this inhibitory effect, the authors suggest, TG2
might act as a host defense against metastatic cells [151]. Interesting-
ly, downregulation of GPR56 was observed in highly metastatic mel-
anoma cells, and hence there is a bypassing of TG2's anti-metastatic
effect [150]. Importantly, it should be noted that extracellular TG2 is
mostly associated with increased migration and invasion, and the
GPR56-dependent anti-metastatic effect of TG2 in melanoma cells is
an exception to this general observation.
It is a well-established notion that the increased attachment to
ECM has a positive effect on cell survival; because, in the absence of
this attachment, normally adherent cells die through a process called
‘anoikis’ [152]. Cell surface TG2 hence promotes survival by promot-
ing attachment to the matrix, thereby protects cell from anoikis
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As an important side note, the TG2 inhibitor KCC009 was reported
to ‘block the remodeling of ﬁbronectin in the ECM in glioblastomas in
both in vitro and in vivo studies and sensitize glioblastomas to chemo-
therapy’ [153]; which prompted the authors to conclude that TG2 is
involved in ﬁbronectin remodeling and resistance to chemotherapy.
In a more recent study, the same group reported that molecules relat-
ed to KCC009, but lack the TG2 inhibitory effect, retained their pro-
death effects [154]. This observation highlights the importance of
caution while interpreting the results obtained with TG2 inhibitors.
The last decade witnessed the exponential growth of publica-
tions about cell surface TG2, which has proven to be extremely im-
portant in many physiological and pathological processes. In the
current decade, it is not unreasonable to expect the translation of
this new body of information into pharmaceutical and possible
clinical studies.10. Transcriptional regulation by TG2
Although the major TG2 pool inside the cell is cytosolic, the pres-
ence of nuclear TG2 is well-documented [71,72] (Fig. 2). More inter-
estingly, a pattern is emerging about TG2: stress induced nuclear
localization. Increasing numbers of stressors are being reported to in-
crease the amount of TG2 in the nucleus. Earlier reports suggested
that sphingosine-induced cell death [14], glutamate induced excito-
toxicity [155] and maitotoxin induced calcium increases [71] caused
nuclear accumulation of TG2. A more recent report, using a different
cell model and an ionophore, reinforced previous ﬁndings which
showed that elevated intracellular calcium levels increase transloca-
tion of TG2 to the nucleus [156]. Tatsukawa et al. demonstrate very
clearly that the ethanol induced apoptosis in hepatic cells was accom-
panied by a signiﬁcant TG2 accumulation in the nucleus [157]. We
[114,115] and others [84] have shown that hypoxic/ischemic stress sig-
niﬁcantly increases the levels of nuclear TG2. In addition to stress condi-
tions, Balajthy et al. reported that TG2 translocated into the nucleus
during the differentiation of NB4 cells to neutrophil granulocytes




Fig. 6. Transcriptional regulation by TG2. (a) TG2 transamidates I-кB, leading to NF-кB activa
activation of CREB. (d) TG2 downregulates MMP-9 expression and promoter activity. (e) TG
expression. (g) TG2 crosslinks Sp1 in response to ethanol and downregulates Sp1 regulatedthis nuclear accumulation, and it is becoming evident that this outcome
is most likely transcriptional regulation [78,84,114,115,157,159].
A growing number of studies indicate that TG2 plays a role in mod-
ulating transcriptional processes (Fig. 6). Our previous studies focus on
the role of TG2 in HIF signaling. We have shown [36,114,115] that TG2:
i) accumulates in the nucleus in response to hypoxic and ischemic
stress, ii) can interact with HIF1β and suppress HIF-dependent tran-
scription (Fig. 6), iii) is protective in in vivo and ex vivo ischemiamodels
and, iv) nuclear localization of TG2 enhance its protective effect.
In addition to our studies, a very recent study showed that nuclear
TG2 may mediate transcriptional dysregulation in cellular models of
Huntington disease [78]. This is intriguing given the fact that TG2 is
upregulated in Huntington disease patient brains [160] and there is
increasing evidence that malfunctioning transcriptional regulation
likely contributes to the progression of Huntington disease [161]. In
the study by McConoughey and co-workers [78] data was presented
suggesting that: i) TG2 suppresses PGC-1α and cyt-c expression at
the transcriptional level (Fig. 6); ii) nuclear localization of TG2 is nec-
essary for the transcriptional suppression; iii) TG2 is recruited to the
promoters of cyt-c and PGC-1α; iv) recruitment of TG2 to the cyt-c
promoter is increased at least ten fold in mutant huntingtin cells; v)
wild-type TG2 suppressed the promoter activity of cyt-c, whereas
transamidating-inactive TG2 did not, and vi) an inhibitor of TG2,
ZDON, increased PGC-1α and cyt-c expression [78]. As an important
note, all these TG2-mediated effects were observed in the presence
of mutant huntingtin and there were little, if any, effect in wild type
huntingtin expressing cells [78].
The work done by Tatsukawa et al. constitutes another important
example of TG2-mediated transcriptional regulation [157]. In this
study, the authors show that: i) ethanol induces nuclear accumulation
of TG2, ii) TG2 crosslinks and inactivates Sp1 in response to ethanol
treatment (Fig. 6), iii) ethanol-induced apoptosis involves TG2 mediat-
ed inactivation of Sp1 and iv) TG2-dependent apoptosis accompanies
reduced expression of Sp1 targets. This detailed study shows that TG2
suppresses transcription of a certain set of genes (a subset of Sp1 target
genes) in a transamidating activity dependent manner. The major
shortcoming of this study was the lack of the use of transamidating in-
active mutants. Although the authors used TG2 inhibitors cystamine
and putrescine [157], these are not selective or speciﬁc inhibitors.c
d
g
tion. (b) TG2 activates NF-кB transcriptional activity. (c) TG2 increases cAMP, leading to
2 suppresses HRE activity in response to hypoxia. (f) TG2 suppresses PGC-1α and cyt-c
gene transcription.
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in a report by Ahn et al. [159]. In this study they showed that TG2
overexpression suppresses matrix metalloproteinase-9 (MMP-9) ex-
pression and MMP-9 promoter activity (Fig. 6), which was reversed
by TG2 siRNA [159]. Furthermore, the authors suggest that TG2 di-
minishes c-jun–c-fos interactions and their recruitment to the AP-1
binding sites [159]. Although there are some weaknesses in the
study, the data clearly demonstrates that TG2 suppresses MMP-9
message, protein and promoter activity.
In addition to direct regulation of transcriptional processes by nu-
clear TG2, cytosolic TG2 may also indirectly regulate transcriptional
processes. One of the pathways that may be regulated by cytosolic
TG2 is the NF-κB pathway. It is not totally clear how TG2 activates
NF-κB and it is deﬁnitely possible that more than one mechanism ex-
ists [162]. The current understanding of NF-κB activation by TG2 re-
lies on the latter's ability to polymerize inhibitory subunit alpha of
NF-κB (I-κB), through its transamidating activity [163] (Fig. 6). As a
result of this polymerization, NF-κB dissociates from the inhibitor
and translocates to the nucleus where it activates transcription
[163]. The authors found that TG2 inhibition prevents NF-κB activa-
tion [163]. Other reports supporting this hypothesis have been pub-
lished [84,164,165]. In addition to its role in I-κB polymerization, TG2
might regulate the NF-κB pathway through different mechanisms
[156]. Very recent data from Mehta and his colleagues show that a
transamidating inactive mutant of TG2 was as effective as wild type in
activating NF-κB transcriptional activity (Kapil Mehta, personal com-
munication). Overall, there is compelling evidence showing that TG2
activates NF-κB; however the involvement of transamidating activity
of TG2 in the activation of NF-κB pathway is yet to be established.
Cytosolic TG2 also regulates the activity of another important tran-
scription factor: cAMP-response element-binding protein (CREB). The
mechanism by which TG2 activates CREB is not yet completely clear.
A study from our group showed that TG2 regulates CREB activity by in-
creasing intracellular cAMP levels [166] (Fig. 6). This increase wasFig. 7. Simpliﬁed hypothetical model showing different roles of TG2 in death/survival parad
localization, conformation and activity state, TG2 can differentially modulate cell death/surv
to control cell death/survival processes are: (i)mediating cell to ECM contacts, thereby trigge
or indirectly to promote survival or facilitate demise.suggested to be the direct result of the transamidase-dependent activa-
tion of adenylyl cyclase [166]. Another study demonstrated that TG2 in-
teracts with protein phosphatase 2 (PP2Aα), a protein that
dephosphorylates and inactivates CREB, and targets it for degradation
[167]. Although the authors show that the transamidating activity is
necessary for CREB activation, they do not showwhether it is necessary
for PP2Aα degradation, therefore, they fell short of showing a causal
link [167]. A third study suggests a completely different mechanism.
Kang et al. [168] argues that TG2 activates CREB by activatingAkt signal-
ing through its adrenergic receptor responsive G-protein function. The
fact that three different groups reported TG2-dependent CREB activa-
tion in different models is a strong indication of the importance of
TG2 in the regulation of CREB activity. However, the mechanism of
this regulation remains to be established.
11. Conclusions
Research on TG2 started approximately 50 years ago when a new
reaction in liver extracts was discovered and the enzyme responsible
for this reaction was named “transglutaminase” [22]. TG2 was consid-
ered solely as a transamidating enzyme until 1987 when its GTP bind-
ing and hydrolyzing activity was deﬁned [31]. Since then, several new
enzymatic functions of TG2 were deﬁned and we are still learning the
extent of its multifunctionality. Although we do not know the most
prominent role of TG2, it appears that its role on the cell surface is
starting to emerge as one of the most important functions. Surprising-
ly, the extracellular role of TG2 is mostly not transamidase activity de-
pendent. This is in line with our and several other groups' observation
that the most important function of TG2 in the cell is not its transami-
dase activity, but other activities.
One of the most curious questions in the TG2 ﬁeld is that why TG2
knockout mice survive if this protein has so many important roles.
The fact that TG2 knockout animals have no major pathologies
makes it very difﬁcult to establish the most prominent function ofigm. The complex circuitry of the cellular processes regulated by TG2. Depending on its
ival processes. Relatively well described mechanisms that are widely exploited by TG2
ring cell survival signaling; (ii) controlling the activities of transcription factors directly
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than a central player, in the processes in which it is involved. Meta-
phorically speaking, it is a ﬁne tuning knob rather than an on/off
switch. In this functional capacity, cells can cope with the absence
of TG2 even though it is involved in many processes.
Of the many cellular processes in which TG2 is involved, deter-
mining cell death/survival processes is obviously an important one
(Fig. 7). Depending on which function of TG2 is involved it can facil-
itate survival or death. In addition to different functions; localization
and conformation state of the protein are also very important in de-
termining the ﬁnal outcome. In the past TG2 was considered to be a
pro-cell death protein, primarily because in severely stressed models
TG2 facilitated apoptosis [101,169] and is upregulated in a variety of
central nervous system pathologies such as chronic progressive neu-
rodegenerative disorders (Huntington disease, Alzheimer disease,
Parkinson disease and progressive supranuclear palsy) [109] or
acute brain injury [170] and stroke models [171]. However, recent
studies from our group [36,114,115] and others [49,125,165,172]
are causing a paradigm shift in the ﬁeld. The new paradigm tends to
depict TG2 more as a prosurvival protein. It is possible to speculate
that the observed upregulation of TG2 in neurodegenerative condi-
tions may be compensatory; i.e., an attempt by the cell to increase
its chances of survival under stress. In addition to an upregulation
of TG2, an increasing numbers of stressors are being reported to ele-
vate the amount of TG2 in the nucleus [14,71,157]. It can be speculat-
ed that accumulating TG2 in the nucleus is the cell's coping response
to the stress. Given this, an important question to be addressed is how
TG2 get into the nucleus. The mechanisms by which TG2 regulates
transcriptional processes also remain to be elucidated. Overall it is
clear that TG2 plays a complex, yet important role in regulating cell
death and cell survival decisions and thoughmuch is knownmuch re-
mains to be learned.Acknowledgements
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